Aeterna Zentaris Inc. (NASDAQ:AEZS) shares traded up 2.4% on Monday . The company traded as high as $3.59 and last traded at $3.45, with a volume of 104,586 shares traded. The stock had previously closed at $3.37.

A number of research analysts have weighed in on the stock. Maxim Group reissued a “buy” rating and set a $11.00 target price on shares of Aeterna Zentaris in a research report on Tuesday, May 10th. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Aeterna Zentaris in a research report on Sunday, July 10th.

The company’s market cap is $33.30 million. The stock has a 50-day moving average of $3.41 and a 200-day moving average of $3.46.

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.